The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Population-based pan-Canadian EGFR-mutation testing program.
M. S. Tsao
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
D. Ionescu
Honoraria - AstraZeneca
G. Chong
Research Funding - AstraZeneca
A. M. Magliocco
No relevant relationships to disclose
D. Soulieres
Research Funding - AstraZeneca
D. Hwang
No relevant relationships to disclose
S. Young
Research Funding - AstraZeneca
C. Wei
No relevant relationships to disclose
I. Bosdet
No relevant relationships to disclose
A. Karsan
No relevant relationships to disclose
A. Spatz
No relevant relationships to disclose
S. Kamel-Reid
Consultant or Advisory Role - AstraZeneca
Research Funding - AstraZeneca